ResokineAlternative Names: aTyr 1920; HisRSN4 - aTyr Pharma; Histidyl-tRNA synthetase - aTyr Pharma; HRS (1-60) - aTyr Pharma; Resected-tRNA synthetase - aTyr Pharma; Resokine IV; Truncated-tRNA synthetase - aTyr Pharma
Latest Information Update: 08 Mar 2016
At a glance
- Originator aTyr Pharma
- Class Amino acids peptides and proteins; Amino acyl-tRNA synthetases; Aminoacyltransferases; Biological proteins; Proteins
- Mechanism of Action Histidine-tRNA ligase modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunological disorders; Inflammatory bowel diseases